Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA ...

argenx SE (NASDAQ:ARGX – Free Report) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) ...

In a report released on October 31, Yaron Werber from TD Cowen maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...

(NASDAQ:ARGX – Get Free Report) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” ...

A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be ...

周二,Wolfe Research将argenx SE (NASDAQ: ARGX)的股票评级从Peerperform上调至Outperform,目标价为697.00美元。该公司预计,在肌炎和PFS项目的推动下,argenx到2025年将呈现积极发展态势,并有望在重症肌无力(MG)市场保持主导地位,尤其是在竞争对手Biohaven和Immunovant发布最新消息后。 Wolfe Research ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA ...